Crossject (ALCJ PA) stock market data APIs
€2.0593
0.01(0.5%)
as of January 16, 2026
Try our APIs with
free plan!
Crossject Financial Data Overview
Price chart is built with
Anychart
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. In addition, the company is developing ZEPIZURE, an emergency treatment for managing epileptic seizures. The company was incorporated in 2001 and is based in Dijon, France.
Prev. Close
2.0593
Open
2.0651
High
2.1013
Low
2.0488
52 wk Range
0.7074-2.695
Market Cap
107 M
Shares Outstanding
52 167 K
Revenue
4 073 K
EPS
-0.1
Beta
0.617
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Crossject data using free add-ons & libraries
Get Crossject Fundamental Data
Crossject Fundamental data includes:
- Net Revenue: 4 073 K
- EBITDA: -9 679 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-31
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Crossject News
New
Crossject announces initiation of coverage by ODDO BHF
Rated “Outperform” with price target of €7.10 Analysts cite $60 million BARDA contract for Crossject’s ZEPIZURE® as validation of platform Dijon, France November 28, 2023, 07:30 CET -- Cros...
Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 14 novembre 2023 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ...
Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 5 octobre 2023 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ),...
Crossject reports financial results and business highlights for first half of 2023
Press Release Crossjectreports financial results and business highlights for first half of 2023 Strong progress in bringing drugs for use in emergency situations towards the market Further strength...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
